Equillium

EQ

시가총액 US$7546만

New preclinical data further characterizes EQ504's coordinated effects across epithelial and immune compartments in intestinal inflammation New preclinical data further characterizes EQ504's coordinated effects across epithelial and immune compartments in intestinal inflammation

On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation

New preclinical data further characterize EQ504's effects on epithelial barrier repair and immune regulation New preclinical data further characterize EQ504's effects on epithelial barrier repair and immune regulation

Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined the company's plans to advance its lead programs, including an oral aryl hydrocarbon receptor, or AhR, modulator for ulcerative colitis and an oral bispecific peptide for celiac disease, during a fireside chat.

LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be participating in a fireside chat at Stifel's 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026 at 12:00pm EDT.

Australian miner EQ Resources said on Tuesday it would take a 10% stake in a joint venture with Nasdaq-listed ​Elmet Group and Blue Moon Metals to restart the ‌Springer tungsten project in Nevada.

LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026 Format: Fireside Chat & 1x1 MeetingsDate: Wednesday, September 9, 2026Time: 9:45 AM EDTWebcast Link: Here H.C.

Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter Cash and cash equivalents of $57.2 million expected to fund operations into 2029 LA JOLLA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update highlighting continued progress in support of EQ504, its potent and selective aryl hydrocarbon receptor (AhR) modulator.

Three-year renewal follows early campaign results that delivered up to 40% increases in average order value and nearly double the conversion rates using ClearLake TORONTO, ON / ACCESS Newswire / June 18, 2026 / EQ Inc. (TSXV:EQ.V) ("EQ Works" or the "Company"), a leader in AI and data-driven software and solutions that empowers brands to better understand, acquire, and retain their most valuable customers, today announced a three-year renewal and expansion of its partnership with a leading Canadian publisher, including the adoption of a SaaS license for its proprietary ClearLake platform. Under the expanded agreement, the publisher's internal teams will gain direct access to ClearLake to independently conduct advanced customer, competitor, and market research using EQ Works' proprietary data and analytics.

LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on June 1, 2026, the Compensation Committee of Equillium's Board of Directors granted an inducement award consisting of nonstatutory stock options to purchase a total of 145,000 shares of common stock to a new employee under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4).